Who
Paul Sweetnam
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Retension Pharmaceuticals.
In numbers
- Trades disclosed
- 4
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Oct 2026
- Last trade
- 13 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —4,026 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —2,640 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,026 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,640 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.